IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, an ...
In early March 2026, Tango Therapeutics and Erasca announced a clinical trial collaboration and supply agreement to test Erasca’s pan-RAS molecular glue ERAS-0015 with Tango’s PRMT5 inhibitor ...
"This study establishes MTAP-del as a biomarker in bladder cancer. We are now ready for a trial in MTAP-del bladder cancer in combination with other inhibitors of the pathway." --Joaquim Bellmunt, MD, ...
Zacks Investment Research on MSN
TNGX stock hits record high on inking collaboration deal with ERAS
Shares of Tango Therapeutics TNGX surged 36.3% on Thursday to a record high after Erasca ERAS announced a clinical trial collaboration and supply agreement with the company. Under the agreement, the ...
Insilico Medicine is heading to the clinic with its seventh pipeline candidate discovered and designed using generative artificial intelligence (AI), a treatment for methylthioadenosine phosphorylase ...
“In breast cancer, MTAP downregulation activates ornithine decarboxylase (ODC) which in turn leads to formation of putrescine which promotes tumor migration, invasion and angiogenesis [15].” “We ...
US-based digital networking solutions provider mTap has announced its launch in India, offering a platform for individuals and businesses to make lasting connections. mTap's digital business card ...
IDEAYA Biosciences begins patient dosing in phase 1 trial of IDE892, a potential best-in-class PRMT5 inhibitor for MTAP-deleted solid tumours: South San Francisco, California Tues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results